HELP ELIGIBLE PATIENTS SAVE ON ALREX
Learn about a savings offer from Bausch + Lomb.
HELP YOUR ELIGIBLE PATIENTS SAVE
Learn about a savings offer from Bausch + Lomb.
SAC, seasonal allergic conjunctivitis.
ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Click here for full Prescribing Information for ALREX.
References: 1. ALREX [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2019. 2. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 1999;106(2):362-369.
ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Click here for full Prescribing Information for ALREX.